- Strategic Partnership
- Bioprocess Development
- Process Analytical Technology (PAT)
- Market Impact
Neutal, Austria February 20, 2025, QBDC GmbH, headquartered in Austria, a pioneering deep tech company dedicated to advancing human health through innovative bioprocessing solutions, today reported that the company has entered a supply agreement with Evonik Operations GmbH to implement the innovative CHO Microarray technology into its Process Analytical Technology of Biomanufacturing.
This agreement represents a significant first step in enhancing the credibility and technological expertise of QBDC in the field of bioprocess development and manufacturing.
In partnership with the renowned company Evonik, QBDC aims to capture a significant share of the bioprocess analytical market.
By integrating epigenetic technology, artificial intelligence, and bioprocess development and manufacturing, we anticipate substantial economic and technological benefits for the pharmaceutical manufacturing industry.
“The collaboration aims to introduce a new AI-driven control system for process technology, positioning the CHO Microarray technology within a new market segment and promoting innovations in the biotech sector”, said Karlheinz Landauer, CEO QBDC”. Currently, the technology is being applied in media development, process and raw material comparability, and AI-supported process development and life-cycle management.” he added.
Over the next 12 months, QBDC is committed to bringing this product to market maturity, with an anticipated initial revenue of €5-6 million in the year 2026. This new technology promises to offer groundbreaking insights into the processes occurring in bioreactors for the biologics market. For the first time, cell development precision forecasting is based on epigenetics and thus on cell development quality and productivity.
Machine learning models will assist in analyzing this vast amount of data, enabling faster and more cost-effective bioprocess development.
“The collaboration aims to significantly benefit the market by reducing process development timelines, improving process understanding, and increasing process robustness. This initiative will also lead to the introduction of higher-quality products with higher yields, while simultaneously reducing CO2 emissions through minimized batch losses.”, states Evonik.
Process Analytical Technology (PAT) is essential in biopharmaceuticals, especially for developing and producing Chinese Hamster Ovary (CHO) cell lines used in monoclonal antibody (mAb) production. The CHO cell line market faces challenges like scaling up production, maintaining cell viability, optimizing yields, and ensuring quality attributes. Enhanced PAT capabilities provide data-driven insights to address these issues.
QBDC’s Epigenetic Digital Data Interface (EDDI) is a transformative tool for predictive analytics and process optimization. Applying Evonik and Illumina microarray technology, EDDI applies broader cellular epigenetics and integrates machine learning (ML) and artificial intelligence (AI) with DNA methylation data. This innovation enhances cell line development and manufacturing efficiency, aligning with regulatory initiatives like the FDA’s PAT framework.
About QBDC GmbH
QBDC GmbH, based in Austria, is a pioneering deep tech company focused on enhancing human health through innovative bioprocessing solutions. Our mission is to create and provide state-of-the-art solutions and services that tackle the most critical challenges in healthcare and life sciences. With a strong emphasis on research and development, QBDC GmbH utilizes cutting-edge technology and a team of world-class scientists to drive advancements in biopharmaceuticals, diagnostics, and personalized medicine.
QBDC GmbH specializes in bioprocess optimization, cell and gene therapy, and novel biologics development. Through strategic partnerships with top academic and industry leaders, we translate scientific discoveries into practical applications that enhance patient outcomes and quality of life.
QBDC offers bioprocessing services and is developing a new process analytical technology based on DNA methylation. This innovation aids the biotech industry in developing manufacturing processes more quickly and efficiently and supports GMP manufacturing to ensure higher quality at lower costs. As a deep-tech company, we leverage the newest ML/AI technology to advance the biotech pharmaceutical industry.
For more information, please visit our website at www.qbdc.com or follow us on LinkedIn.
For Contact
Karlheinz Landauer, PhD
Chief Executive Officer
Neutal, Theodor-Kerry Gasse 3
Austria contact@qbdc.ch
For Media
Kamosys GmbH
Philipp Hahn Philipp.hahn@kamosys.eu
+43 676 5345614